There is strong evidence that intracellular calcium dysregulation plays an important pathological role in Alzheimer's disease, and specifically that beta amyloid may induce increases in intracellular calcium and lead to neuronal cell dysfunction and death. Here we investigated the feasibility of modifying Alzheimer's pathology with the L-type voltage-gated calcium channel blockers verapamil, diltiazem, isradipine and nimodipine. All four compounds protected MC65 neuroblastoma cells from amyloid beta protein precursor Cterminal fragment (APP CTF)-induced neurotoxicity. Isradipine was the most potent blocker, preventing APP CTF neurotoxicity at nanomolar concentrations. Intracellular beta amyloid expression was associated with increased expression of Cav 1.2 calcium channels and increased intracellular calcium influx from the extracellular space. Despite the cytoprotection afforded by calcium channel blockers, amyloid beta oligomer formation was not suppressed. The mechanism of cell death in MC65 cells is appeared to be caspase-3 independent. With the goal of determining if there is sufficient experimental support to move forward with animal trials of isradipine, we determined its bioavailability in the triple transgenic mouse model of AD. Subcutaneous implantation of carrier-bound isradipine (3 μg/g/day) for 60 days resulted in nanomolar concentrations in both the plasma and brain. Taken together, our in vitro results support the theory that calcium blockers exert protective effects downstream of the effects of beta amyloid. Isradipine's neuroprotective effect at concentrations that are clinically relevant and achievable in vitro and in vivo suggests that this particular calcium blocking agent may have therapeutic value in the treatment of Alzheimer's disease.
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Introduction
Alzheimer's disease (AD) is a progressive, age-related neurodegenerative disease that impairs memory and learning by affecting selective neuronal populations predominantly in the hippocampus and cerebral cortex. Accumulation of extracellular beta-amyloid (Aβ) and intracellular neurofibrillary tangles composed of hyperphosphorylated tau are the pathologic hallmarks of AD. In both earlyonset familial and late-onset sporadic forms of AD, a 4-kDa Aβ peptide cleavage product of two key enzymatic reactions mediated by β and γ secretases has been considered a causal factor of AD (Selkoe, 2000 (Selkoe, , 2001 (Selkoe, , 2004 Tanzi and Bertram, 2005) . The fragment sizes of Aβ vary between 39 and 43 amino acid residues, with Aβ40 being the most common species and Aβ42, a longer, hydrophobic species with a tendency to be more fibrillogenic. Recent studies demonstrate that a soluble form of oligomeric Aβ is more toxic than the monomeric form, and consequently a conscious effort has been made to reconstitute oligomers from monomers in the laboratory setting to demonstrate toxicity in neuronal cells (Li et al., 2009; Picone et al., 2009; Pitt et al., 2009; Poon et al., 2009; Sondag et al., 2009) . Evidence from animals models of AD places a particular importance on the accumulation of intraneuronal Aβ oligomers and their role in early pathogenesis of AD (Billings et al., 2005; Golde and Janus, 2005) .
Most of our current knowledge of Aβ oligomer toxicity appears to stem from studies that determine the effects of external application of reconstituted, synthetic oligomers. Although these studies have contributed greatly to our knowledge, models of AD that explore the pathomechanisms of intracellular Aβ oligomers have generally been limited. In vitro studies utilizing human neuroblastoma (MC65) cells appear to overcome, at least partially, the limitations of previous methods because they eliminate the need to externally apply Aβ oligomers. MC65 cells are stably transfected with the amyloid precursor Neurobiology of Disease 41 (2011) 62-70 
